COPD患者血浆金属蛋白激酶及组织抑制物含量的研究

The research on serum concentrations of matrix metalloproteinase-9 and tissue inhibitors of metalloproteinase-1 in COPD patients

目的研究慢性阻塞性肺病(Chronic obstructive pulmonary disease,COPD)患者血清基质金属蛋白酶(Matrix metal-loproteinase,MMP)-9和金属蛋白激酶组织抑制物(Tissue inhibitors of metalloproteinases,TIMPs)-1含量,以探讨它们与气道阻塞之间的关系。方法收集72例COPD,26例支气管哮喘(简称哮喘)以及66例对照患者的静脉血,利用ELISA方法测定上述血清TIMP-1和MMP-9含量,并对COPD进行呼吸功能测定,对TIMP-1、MMP-9含量与第一秒用力肺活量进行相关性分析。结果COPD患者血清TIMP-1含量(193.0±5.3μγ/L)显著高于对照组(119.9±6.5)μg/L和哮喘组(162.1±13.6)μg/L,并与COPD患者的第一秒用力肺活量呈负相关性,MMP-9/TIMP-1摩尔比值低于对照组,COPD急性加重期TIMP-1含量升高。结论血清TIMP-1含量在COPD气道阻塞和急性加重期升高。

Objective To examine the serum concentrations of matrix metalloproteinase （romp） -9 and tissue inhibitors of metalloproteinase （TIMP） -1 concentrations in COPD patients in order to determine their relationship with airway obstruction. Methods Serum samples were obtained from 72 patients with COPD, including 66 control subjects and 26 patients with asthma. TIMP-1 and MMP-9 were determined by ELISA. Results The serum TIMP-1 concentration was significantly higher in COPD patients than that in the control patients and in asthmatic subjects, and was significantly negatively correlated with FEV1 in COPD patients. The MMP-9/TIMP-1 molar ratio was significantly lower in COPD patients than in control subjects. In patients with COPD, the serum TIMP-1 concentration was significantly increased during exacerbation. Conclusion Serum tissue inhibitors of metalloproteinase-1 concentration can be used as a serum marker of airway obstruction and exacerbation in chronic obstructive pulmonary disease patients.